| Identification | Back Directory | [Name]
LYC-55716 | [CAS]
2055536-64-4 | [Synonyms]
LYC-55716
Cintirorgon)
LYC-55716
(LYC55716
Cintirorgon (LYC-55716)
2H-1,4-Benzoxazine-2-propanoic acid, 6-[3-(difluoromethoxy)-5-fluorophenyl]-3,4-dihydro-α,α-dimethyl-4-[[3-(trifluoromethyl)phenyl]sulfonyl]-, (2S)-
(S)-3-(6-(3-(difluoromethoxy)-5-fluorophenyl)-4-((3-(trifluoromethyl)phenyl)sulfonyl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-2-yl)-2,2-dimethylpropanoic acid | [Molecular Formula]
C27H23F6NO6S | [MDL Number]
MFCD31544352 | [MOL File]
2055536-64-4.mol | [Molecular Weight]
603.53 |
| Chemical Properties | Back Directory | [Boiling point ]
669.1±65.0 °C(Predicted) | [density ]
1.417±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO: 100 mg/ml | [form ]
A crystalline solid | [pka]
4.68±0.10(Predicted) | [color ]
White to off-white | [InChIKey]
GULSIMHVQYBADX-XKGZFIRZNA-N | [SMILES]
S(C1C=CC=C(C(F)(F)F)C=1)(N1C[C@H](CC(C)(C)C(=O)O)OC2=CC=C(C3C=C(F)C=C(OC(F)F)C=3)C=C12)(=O)=O |&1:13,r| |
| Hazard Information | Back Directory | [Uses]
Cintirorgon (LYC-55716) is a first-in-class, selective and orally bioavailable RORγ agonist. Cintirorgon (LYC-55716) modulates gene expression of RORγ expressing T lymphocyte immune cells, resulting in enhanced effector function, as well as decreased immunosuppression, resulting in decreased tumor growth, and improved survival[1][2]. | [in vivo]
Upon oral administration of RORγ agonist Cintirorgon (LYC-55716), this agent selectively binds to the nuclear receptor transcription factor RORγ, forming a receptor complex that translocates to the nucleus, and binds to ROR response elements (ROREs), enhancing the function, proliferation and survival of type 17 T cells, including Th17 (helper T cells) and Tc17 (cytotoxic T cells). RORγ, the nuclear receptor transcription factor that is involved in Th17/Tc17 differentiation, plays a key role in immune activation. Cintirorgon (LYC-55716) is also orally bioavailable, while the new generation of immuno-oncology drugs-ncluding PD-1/PD-L1 inhibitors are delivered by injection[1]. | [storage]
Store at -20°C | [References]
[1] Lycera Announces Initiation of Phase 1/2a Study ARGON of Immuno-Oncology Candidate LYC-55716 in Patients with Advanced Solid Tumors. Jan 04, 2017. |
|
| Company Name: |
BOC Sciences
|
| Tel: |
|
| Website: |
https://www.bocsci.com |
|